Eisai will host its annual information meeting which will include information on LEQEMBI® (lecanemab-irmb).
Materials and an audio webcast will also be posted on the Eisai website following its investor event on Friday, March 8 at 1:30 pm JST/Thursday, March 7 at 11:30 pm ET.
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human
